BENSALEM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to howardsmith@howardsmithla ...

Core Insights - Berger Montague PC is investigating claims against Novo Nordisk A/S under federal securities laws following a class action lawsuit filed against the company [1][2]. Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2].

Group 1 - The core issue involves a securities fraud investigation against Spectrum Pharmaceuticals, Inc. related to misleading statements about its Pinnacle Study for the drug poziotinib, aimed at lung cancer treatment [3] - The class action lawsuit pertains to investors who acquired Spectrum shares between March 17, 2022, and September 22, 2022, during which the company faced significant challenges [1][2] - Spectrum's shares were delisted following its merger with Assertio Holdings, Inc., indicating potential financial instability and regulatory scrutiny [3] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representatives in the class action [2] - Berger Montague PC, a law firm with extensive experience in securities class action litigation, is leading the investigation on behalf of affected investors [5]

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Company Background - Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs in the U.S. [1] - The lawsuit claims that Unicycive misrepresented the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2]. - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. Group 2: Recent Developments - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party manufacturing vendor, which impacted discussions regarding the drug label [3]. - Following this announcement, Unicycive's stock price dropped over 40% [3]. - On June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA, further citing the cGMP deficiencies, leading to an additional stock price decline of nearly 30%, closing at $4.77 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Unicycive and can contact Robbins LLP to serve as lead plaintiff before the October 14, 2025 deadline [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or f ...

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose risks related to Nexplanon sales growth, which impacted investor expectations and stock performance [1][3]. Summary by Sections Lawsuit Details - The lawsuit represents purchasers of Organon securities from November 3, 2022, to April 30, 2025, alleging that the company did not disclose a higher risk of loss of exclusivity and price erosion for Nexplanon [1][3]. Investor Information - Investors who acquired Organon securities during the class period have until July 22, 2025, to seek appointment as lead plaintiff [2]. Financial Impact - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [4]. - Following this announcement, Organon’s stock price fell by $3.48, approximately 27%, from $12.93 to $9.45 per share [4].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Group 1: Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Group 2: Financial Disclosures and Stock Impact - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [5]. - Following the October announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors during the Class Period from August 8, 2024, to February 26, 2025 [1][3]. Company Overview - Viatris is a healthcare company based in Canonsburg, PA, that provides medicines to one billion patients globally [2]. Legal Context - The lawsuit claims that Viatris misled investors by downplaying the consequences of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. Food and Drug Administration [3]. - Investors who purchased Viatris securities during the Class Period have until June 3, 2025, to seek appointment as lead plaintiff [2]. Law Firm Background - Berger Montague, the law firm handling the case, has been involved in securities class action litigation since 1970 and has represented both individual and institutional investors [5].

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for alleged misconduct during the Class Period from March 13, 2023, to March 11, 2025 [1][2]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Allegations and Impact - A report published by medical journal STAT on June 4, 2024, accused Zynex of an "oversupplying scheme," where the company allegedly sent excessive supplies to patients to bill insurers for inflated amounts, leading to insurers removing Zynex from their networks [3]. - Following the publication of the report, Zynex's stock price dropped by $0.50 per share, or 5%, closing at $9.35 on June 4, 2024 [3]. Financial Performance - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 and the full year of 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare as they reviewed prior claims [4]. - The announcement of the revenue shortfall resulted in a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51%, closing at $3.41 on March 12, 2025 [4].